Home > Oncology > ASCO 2020 > Lung Cancer > MET-amplified advanced NSCLC responds well to MET inhibitor capmatinib

MET-amplified advanced NSCLC responds well to MET inhibitor capmatinib

*MET* mutations and *MET* amplifications are reported in 1-6% of patients with non–small cell lung cancer (NSCLC). In the ongoing, multicohort phase 2 GEOMETRY trial, patients with stage III/IV NSCLC and high-level *MET* amplification (gene copy number >10) responded well to capmatinib, a highly potent and selective inhibitor of the MET receptor tyrosine kinase.

In the GEOMETRY trial, 84 patients with high-level *MET* amplification (*ALK* and *EGFR* wildtype, stage IIIB/IV) received capmatinib 400 mg twice daily (n=15 were treatment-naïve, n=69 were second or third line). The primary endpoint of the trial was the objective response rate (ORR), while secondary endpoints were duration of response (DOR), progression-free survival (PFS), and overall survival (OS).

“The ORR in the treatment-naïve patients was 40%, and 29% in the pre-treated patients”, reported Prof. Jürgen Wolf (University Hospital Cologne, Germany) [1]. “In the majority of patients thes...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on